Kyoto University Hospital
Kyoto, Japan
Location status: Recruiting
Location contact
Erika Yamamoto, MD, PhD
CONTACT
Takeshi Kimura, MD, PhD
CONTACT
Takeshi Kimura, MD, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05347069
The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.
Interested in participating?
Request Info20 year and older
All sexes
Interventional
Phase 4
Kyoto, Japan
Location status: Recruiting
Erika Yamamoto, MD, PhD
CONTACT
Takeshi Kimura, MD, PhD
CONTACT
Takeshi Kimura, MD, PhD
PRINCIPAL_INVESTIGATOR
Aspirin for secondary prevention in the acute phase of acute coronary syndromes has been established. Although it is still disputable about the duration, there is also a consensus for antiplatelet therapy in patients after percutaneous coronary revascularization. On the other hand, several large randomized clinical trials (RCTs) have shown that aspirin treatment for primary prevention of cardiovascular events increases bleeding events and does not provide net clinical benefit.Patient with chronic coronary syndromes (CCS) but not eligible for revascularization do not belong to any of these categories and there is no evidence on the efficacy of aspirin in this population. Therefore, we designed a multicenter, randomized, open-label study to evaluate the efficacy and safety of aspirin in patients with CCS who are not eligible for revascularization.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Aspirin 100 mg/day
No aspirin administered
Time frame: 5 years
Composite of all-cause death, myocardial infarction, ischemic stroke, coronary revascularization, peripheral revascularization, or critical limb ischemia
Time frame: 5 years
As classified by Academic Research Consortium (ARC) (Circulation. 2007;115:2344-2351).
Time frame: 5 years
As classified by Academic Research Consortium (ARC): However, the sensitivity is too high for the evaluation with Troponin of the peri-procedural MI, thus CKMB will be used.
Time frame: 5 years
Ischemic stroke is defined as acute onset of a neurological deficit that persists for at least 24 hours and is the result of a disturbance of the cerebral circulation due to ischemia. Deficits that last ≤ 24 hours are due to transient ischemic neurological attack and are not classified in this category.
Time frame: 5 years
The revascularization that meets the following criteria is considered as clinically indicated revascularization. Presence/absence of clinical findings is judged by the operator of the procedure before the revascularization.
Time frame: 5 years
The revascularization that meets the following criteria is considered as clinically indicated revascularization. Presence/absence of clinical findings is judged by the operator of the procedure before the revascularization.
Time frame: 5 years
Critical limb ischemia is defined by chronic ischemic pain at rest and/or presence of ischemic skin lesions (gangrene or ulcerations).
Time frame: 5 years
Time frame: 5 years
Bleeding/Hemorrhagic Complications will be evaluated using the Bleeding Academic Research Consortium (BARC) definition. Major bleeding is defined as BARC 3 or 5.
Time frame: 5 years
An unplanned hospitalization with heart failure. Heart failure is defined by the modified Framingham criteria as follow:
[Major Criteria] 1) Paroxysmal nocturnal dyspnea 2) Orthopnea 3) Neck-vein distension 4) Rales 5) Acute pulmonary edema [Minor Criteria]
Time frame: 5 years
Time frame: 5 years
Cancer death is defined as death from cancer cause.
Time frame: 5 years
Composite of all-cause mortality, myocardial infarction, ischemic stroke, coronary revascularization, lower extremity revascularization, critical lower extremity ischemia, major bleeding, hospital admission for heart failure, cancer death
Contact information is provided by the study sponsor or research team.
Erika Yamamoto, MD, PhD
CONTACT
Takeshi Kimura, MD, PhD
CONTACT
Takeshi Morimoto
Other
Acronym: ASA-IN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07063147
Angina Pectoris, Angina, Stable
Tianjin, China
View Trial DetailsNCT06606821
Angina Pectoris, Angina, Stable
Copenhagen, Denmark
View Trial DetailsNCT07592507
Angina Pectoris, Angina, Stable
View Trial DetailsNCT07579624
Acute Coronary Syndrome, Acute Coronary Syndromes
Moscow, Russia
View Trial Details